UPDATE: SECuRE Trial, Another Complete Responder

A striking new update from the ongoing SECuRE trial has revealed yet another participant achieving undetectable PSA levels alongside a completely negative PSMA PET scan, underscoring the potential of ⁶⁷Cu-SAR-bisPSMA in advanced prostate cancer treatment. This 76-year-old patient, facing progressive metastatic castration-resistant prostate cancer (mCRPC) 15 years after initial diagnosis, started with a baseline PSA of 3.25 ng/mL and saw levels drop to undetectable just seven weeks following the first 8 GBq treatment cycle. By the second cycle, imaging confirmed no detectable PSMA-avid disease, with only mild, self-resolving side effects like altered taste and fatigue reported. No hematological toxicity or renal concerns emerged.

This result marks the fifth patient in the program to reach undetectable disease status by radiographic measures, building on a previously highlighted case where a patient sustained this response through a fourth cycle with preserved quality of life. The trial, now advancing through its Phase II cohort expansion, continues dosing up to 6 cycles at 8 GBq while incorporating combinations like enzalutamide for select participants, with enrollment targeted to complete 24 patients by later this year. Earlier data from pre-chemotherapy cohorts showed 92% of patients experiencing greater than 35% PSA reductions, including 46% with ≥80% drops, signaling consistent activity across diverse mCRPC cases.

As the study progresses toward Phase III readiness, the focus shifts to response durability and optimal sequencing alongside established therapies like ARPIs—critical data for clinicians weighing radioligand options in the evolving mCRPC landscape. Patients tracking PSMA-targeted innovations will watch closely as recruitment continues through 2026, potentially positioning this copper-based approach as a meaningful addition to the toolkit.

Source.